chr7:100318091:> Detail (hg19)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr7:100,318,091-100,321,323 |
hg38 | chr7:100,720,468-100,723,700 |
HGVS
Type | Transcript | Protein |
---|---|---|
Summary
MGeND
Clinical significance | |
Variant entry | |
GWAS entry | |
Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
Clinical Significance | |
Review star | [No Data.] |
Show details |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.006 | squamous cell carcinoma | Human tumours from oral squamous cell cancer were xenotransplanted to nude mice ... | BeFree,LHGDN | 25182342 | Detail |
0.004 | Cardiovascular Diseases | However, until now only a handful number of genetic variants were reported to be... | BeFree,LHGDN | 25169573 | Detail |
0.120 | CNS disorder | NA | BeFree,CTD_human | Detail | |
<0.001 | cerebral infarction | NA | BeFree | Detail | |
0.003 | brain ischemia | NA | BeFree,LHGDN | Detail | |
0.080 | Transient ischemic attack | NA | RGD | Detail | |
<0.001 | Malignant tumor of cervix | NA | BeFree | Detail | |
0.120 | Cognition Disorders | NA | CTD_human | Detail | |
<0.001 | colorectal carcinoma | NA | BeFree | Detail | |
<0.001 | cystic fibrosis | NA | BeFree | Detail | |
0.003 | Cyst | NA | BeFree,LHGDN | Detail | |
<0.001 | Dehydration | NA | BeFree | Detail | |
0.080 | Dementia, Vascular | NA | RGD | Detail | |
0.002 | Dermatitis, Atopic | NA | GAD | Detail | |
0.002 | Diabetes | However, until now only a handful number of genetic variants were reported to be... | BeFree | 25169573 | Detail |
0.002 | diabetes mellitus | However, until now only a handful number of genetic variants were reported to be... | BeFree | 25169573 | Detail |
0.002 | Diabetes Mellitus, Insulin-Dependent | NA | GAD | Detail | |
0.006 | Diabetes Mellitus, Non-Insulin-Dependent | The EPO genotype in Chinese patients with type 2 diabetes is associated with ane... | BeFree,GAD | 25656761 | Detail |
0.003 | Diabetic Nephropathy | Genetic variants in angiotensin-converting enzyme (ACE), tumor necrosis factor-a... | BeFree,GAD | 25656761 | Detail |
0.013 | diabetic retinopathy | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Drug abuse | NA | BeFree | Detail | |
0.121 | Experimental Autoimmune Encephalomyelitis | NA | BeFree,CTD_human | Detail | |
0.003 | Endometrial Neoplasms | NA | LHGDN | Detail | |
0.003 | endometriosis | NA | LHGDN | Detail | |
<0.001 | Ependymoma | NA | BeFree | Detail | |
<0.001 | Hyperplasia erythroid | NA | BeFree | Detail | |
<0.001 | Fanconi anemia | NA | BeFree | Detail | |
0.120 | Fatigue | NA | BeFree,CTD_human | Detail | |
<0.001 | Fatty Liver | The loss of all PHD isoforms results in both polycythemia, which is caused by Ep... | BeFree | 26012551 | Detail |
0.080 | Fetal Distress | NA | RGD | Detail | |
0.005 | Fibrosis | NA | LHGDN | Detail | |
<0.001 | Friedreich ataxia | NA | BeFree | Detail | |
0.003 | Glaucoma, Open-Angle | NA | LHGDN | Detail | |
0.001 | glioblastoma | Therefore, pEpo-NI2-SV-HSVtk/PEI-Dexa complex may be useful for glioblastoma-spe... | BeFree | 24467192 | Detail |
0.001 | Glioma | It has been recently reported that erythropoietin (EPO) and its receptor (EPOR) ... | BeFree | 25544764 | Detail |
0.002 | Hay fever | NA | GAD | Detail | |
0.003 | Head and Neck Neoplasms | NA | LHGDN | Detail | |
0.121 | Heart Diseases | NA | BeFree,CTD_human | Detail | |
<0.001 | Heart failure | NA | BeFree | Detail | |
<0.001 | congestive heart failure | NA | BeFree | Detail | |
0.120 | Ventricular Septal Defects | NA | CTD_human | Detail | |
<0.001 | hemochromatosis | NA | BeFree | Detail | |
<0.001 | Hemoglobinopathies | NA | BeFree | Detail | |
0.120 | hemolytic-uremic syndrome | NA | CTD_human | Detail | |
<0.001 | hepatitis | NA | BeFree | Detail | |
<0.001 | hepatitis A | NA | BeFree | Detail | |
<0.001 | Hepatitis, Chronic | NA | BeFree | Detail | |
0.001 | hepatitis C | NA | BeFree | Detail | |
<0.001 | Herpes Simplex Infections | NA | BeFree | Detail | |
0.002 | Von Hippel-Lindau syndrome | NA | BeFree | Detail | |
0.001 | HIV Infections | NA | BeFree | Detail | |
<0.001 | Hodgkin Disease | NA | BeFree | Detail | |
<0.001 | Huntington disease | NA | BeFree | Detail | |
<0.001 | Hydrocephalus, Normal Pressure | NA | BeFree | Detail | |
<0.001 | Hypergammaglobulinemia | NA | BeFree | Detail | |
0.003 | Hyperplasia | NA | LHGDN | Detail | |
0.122 | Hypertensive disease | However, treatment can result in rhEPO levels greatly exceeding the normal physi... | BeFree,CTD_human | 25392999 | Detail |
<0.001 | pulmonary hypertension | NA | BeFree | Detail | |
<0.001 | Immunologic Deficiency Syndromes | NA | BeFree | Detail | |
0.120 | Inflammation | NA | CTD_human | Detail | |
<0.001 | Inflammatory Bowel Diseases | NA | BeFree | Detail | |
0.011 | ischemia | Recombinant human erythropoietin augments angiogenic responses in a neonatal rat... | BeFree,LHGDN | 24969821 | Detail |
0.122 | Kidney Diseases | Accelerating Epo production in hepatocytes is one plausible therapeutic strategy... | BeFree,CTD_human | 26012551 | Detail |
0.002 | Kidney Failure, Acute | NA | GAD | Detail | |
0.128 | Kidney Failure, Chronic | NA | BeFree,CTD_human,LHGDN | Detail | |
<0.001 | Polycystic Kidney Diseases | NA | BeFree | Detail | |
<0.001 | Fibroid Tumor | Our study suggests one possible mechanism by which some uterine leiomyomas reach... | BeFree | 25724399 | Detail |
0.003 | leukemia | NA | BeFree | Detail | |
0.006 | chronic lymphocytic leukemia | NA | BeFree,GAD,LHGDN | Detail | |
0.005 | Acute Erythroblastic Leukemia | NA | BeFree | Detail | |
<0.001 | Acute lymphocytic leukemia | NA | BeFree | Detail | |
<0.001 | Acute Megakaryocytic Leukemias | NA | BeFree | Detail | |
0.003 | Leukemia, Myelocytic, Acute | NA | BeFree,GAD | Detail | |
0.003 | Myeloid Leukemia, Chronic | NA | BeFree,GAD | Detail | |
<0.001 | Leukemia, Myelomonocytic, Chronic | NA | BeFree | Detail | |
0.003 | Leukomalacia, Periventricular | NA | LHGDN | Detail | |
<0.001 | leukopenia | Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplemen... | BeFree | 25469044 | Detail |
0.006 | Liver neoplasms | NA | BeFree | Detail | |
0.003 | Chronic Obstructive Airway Disease | NA | LHGDN | Detail | |
<0.001 | malaria | NA | BeFree | Detail | |
<0.001 | Malaria, Cerebral | NA | BeFree | Detail | |
0.124 | melanoma | NA | BeFree,CTD_human,LHGDN | Detail | |
<0.001 | multiple endocrine neoplasia type 2A | NA | BeFree | Detail | |
<0.001 | meningioma | NA | BeFree | Detail | |
<0.001 | Mesothelioma | NA | BeFree | Detail | |
<0.001 | Monoclonal Gammopathy of Undetermined Significance | NA | BeFree | Detail | |
<0.001 | Monosomy | NA | BeFree | Detail | |
0.001 | multiple myeloma | NA | BeFree | Detail | |
<0.001 | multiple sclerosis | NA | BeFree | Detail | |
<0.001 | Myelodysplasia | NA | BeFree | Detail | |
0.001 | myelofibrosis | NA | BeFree | Detail | |
<0.001 | Myeloproliferative disease | NA | BeFree | Detail | |
0.122 | myocardial infarction | NA | BeFree,CTD_human | Detail | |
0.120 | Neoplasm Invasiveness | NA | CTD_human | Detail | |
0.123 | Neoplasm Metastasis | NA | BeFree,CTD_human,LHGDN | Detail | |
0.120 | Nerve Degeneration | NA | CTD_human | Detail | |
<0.001 | nervous system disorder | NA | BeFree | Detail | |
<0.001 | Nervous System Neoplasms | NA | BeFree | Detail | |
0.080 | Neuritis, Autoimmune, Experimental | NA | RGD | Detail | |
0.002 | neuroblastoma | NA | BeFree | Detail | |
<0.001 | neutropenia | Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplemen... | BeFree | 25469044 | Detail |
<0.001 | obesity | NA | BeFree | Detail | |
<0.001 | ovarian carcinoma | NA | BeFree | Detail | |
0.121 | pancytopenia | Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone m... | BeFree,CTD_human | 25970251 | Detail |
<0.001 | Peripheral Nervous System Neoplasms | NA | BeFree | Detail | |
0.003 | pheochromocytoma | NA | BeFree,LHGDN | Detail | |
<0.001 | Pituitary Diseases | NA | BeFree | Detail | |
<0.001 | plasmacytoma | NA | BeFree | Detail | |
0.019 | polycythemia | Due to the unique association of patients' polycythemia with borderline or mildl... | BeFree | 25263965 | Detail |
0.012 | polycythemia vera | NA | BeFree | Detail | |
<0.001 | Adenomatous Polyposis Coli | NA | BeFree | Detail | |
0.005 | Preleukemia | NA | BeFree,GAD | Detail | |
0.003 | Prostatic Neoplasms | NA | LHGDN | Detail | |
0.120 | pulmonary embolism | NA | CTD_human | Detail | |
<0.001 | pure red-cell aplasia | NA | BeFree | Detail | |
0.002 | kidney failure | NA | BeFree | Detail | |
0.003 | Reperfusion Injury | NA | LHGDN | Detail | |
<0.001 | Respiratory Distress Syndrome, Newborn | NA | BeFree | Detail | |
0.001 | retinal degeneration | NA | BeFree | Detail | |
0.080 | retinal detachment | NA | RGD | Detail | |
0.002 | Retinal Diseases | However, until now only a handful number of genetic variants were reported to be... | BeFree | 25169573 | Detail |
0.003 | Retinal Neovascularization | NA | LHGDN | Detail | |
0.003 | retinopathy of prematurity | NA | BeFree,GAD | Detail | |
0.002 | Rhinitis, Allergic, Perennial | NA | GAD | Detail | |
<0.001 | Salmonella infections | NA | BeFree | Detail | |
0.120 | Sarcoma, Experimental | NA | CTD_human | Detail | |
<0.001 | schizophrenia | NA | BeFree | Detail | |
0.080 | Seizures | NA | RGD | Detail | |
0.120 | Shock, Cardiogenic | NA | CTD_human | Detail | |
<0.001 | Shy-Drager Syndrome | NA | BeFree | Detail | |
<0.001 | Sleep Apnea Syndromes | NA | BeFree | Detail | |
0.120 | status epilepticus | NA | CTD_human | Detail | |
0.120 | gastric ulcer | NA | CTD_human | Detail | |
<0.001 | Cerebrovascular accident | NA | BeFree | Detail | |
<0.001 | Superinfection | NA | BeFree | Detail | |
<0.001 | thalassemia | NA | BeFree | Detail | |
0.002 | Thrombocythemia, Essential | NA | BeFree | Detail | |
0.120 | thrombocytopenia | NA | CTD_human | Detail | |
0.120 | thrombosis | NA | CTD_human | Detail | |
0.123 | Thyroid Neoplasm | NA | CTD_human,LHGDN | Detail | |
<0.001 | trypanosomiasis | NA | BeFree | Detail | |
0.120 | uremia | NA | BeFree,CTD_human | Detail | |
<0.001 | Uterine Fibroids | Aberrant expression of erythropoietin in uterine leiomyoma: implications in tumo... | BeFree | 25724399 | Detail |
0.120 | Vascular Diseases | NA | CTD_human | Detail | |
0.120 | Venous Thrombosis | NA | CTD_human | Detail | |
0.120 | Ventricular fibrillation | NA | CTD_human | Detail | |
0.120 | Tachycardia, Ventricular | NA | CTD_human | Detail | |
<0.001 | severe combined immunodeficiency | NA | BeFree | Detail | |
<0.001 | Central Nervous System Neoplasms | NA | BeFree | Detail | |
0.003 | Polyendocrinopathies, Autoimmune | NA | LHGDN | Detail | |
<0.001 | Polycystic Kidney, Autosomal Dominant | NA | BeFree | Detail | |
<0.001 | Synovial Cyst | NA | BeFree | Detail | |
<0.001 | Coronary Occlusion | NA | BeFree | Detail | |
0.120 | polyneuropathy | NA | CTD_human | Detail | |
0.003 | Familial erythrocytosis | Some patients with primary hereditary erythrocytosis exhibit a mutation in the e... | BeFree | 25189721 | Detail |
<0.001 | Malignant neoplasm of brain | NA | BeFree | Detail | |
0.001 | proliferative diabetic retinopathy | NA | BeFree | Detail | |
<0.001 | acute myocardial infarction | NA | BeFree | Detail | |
<0.001 | anemia of prematurity | NA | BeFree | Detail | |
<0.001 | iron deficiency anemia | NA | BeFree | Detail | |
<0.001 | Hypoplastic anemia | NA | BeFree | Detail | |
0.002 | Tumor Progression | NA | BeFree | Detail | |
<0.001 | hepatoblastoma | NA | BeFree | Detail | |
<0.001 | embryonal carcinoma | NA | BeFree | Detail | |
0.080 | cholangiocarcinoma | NA | BeFree,RGD | Detail | |
<0.001 | hemangioblastoma | NA | BeFree | Detail | |
<0.001 | Lesion of brain | NA | BeFree | Detail | |
<0.001 | Anemia, severe | NA | BeFree | Detail | |
0.002 | Iron deficiency | NA | BeFree | Detail | |
0.003 | Disease Progression | NA | LHGDN | Detail | |
<0.001 | Chronic myocardial ischemia | NA | BeFree | Detail | |
<0.001 | Miller Dieker syndrome | NA | BeFree | Detail | |
<0.001 | Cyanotic congenital heart disease | NA | BeFree | Detail | |
<0.001 | Ichthyosis linearis circumflexa | Interestingly, the highest level of EPO/% retic ratio as indicated for EPO non-r... | BeFree | 25477265 | Detail |
<0.001 | dyskeratosis congenita | NA | BeFree | Detail | |
<0.001 | Juvenile hemochromatosis | NA | BeFree | Detail | |
<0.001 | Simple renal cyst | NA | BeFree | Detail | |
<0.001 | Impaired glucose tolerance | NA | BeFree | Detail | |
<0.001 | Microcytic hypochromic anemia (disorder) | NA | BeFree | Detail | |
<0.001 | Anemia of chronic renal failure | NA | BeFree | Detail | |
<0.001 | Erythroblastosis | NA | BeFree | Detail | |
<0.001 | Liver and Intrahepatic Biliary Tract Carcinoma | NA | BeFree | Detail | |
<0.001 | Conventional (Clear Cell) Renal Cell Carcinoma | NA | BeFree | Detail | |
0.001 | Solid tumour | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma of pancreas | NA | BeFree | Detail | |
<0.001 | Iron Overload | NA | BeFree | Detail | |
<0.001 | cervix carcinoma | The aim of this study is to explore a cause-oriented therapy for patients with u... | BeFree | 25874769 | Detail |
<0.001 | Anastomosis | NA | BeFree | Detail | |
<0.001 | Impaired cognition | NA | BeFree | Detail | |
<0.001 | Proliferative retinopathy | NA | BeFree | Detail | |
<0.001 | Anterior myocardial infarction | NA | BeFree | Detail | |
<0.001 | sialuria | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of liver | NA | BeFree | Detail | |
<0.001 | malignant mesothelioma | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of prostate | NA | BeFree | Detail | |
<0.001 | Hereditary hemochromatosis | NA | BeFree | Detail | |
<0.001 | multiple system atrophy | NA | BeFree | Detail | |
0.003 | Chronic Kidney Insufficiency | NA | BeFree | Detail | |
<0.001 | neuropathy | NA | BeFree | Detail | |
<0.001 | Anemia of renal disease | NA | BeFree | Detail | |
<0.001 | Beta thalassemia intermedia | NA | BeFree | Detail | |
0.003 | Sleep Apnea, Obstructive | NA | LHGDN | Detail | |
0.120 | Neurodegenerative Disorders | NA | BeFree,CTD_human | Detail | |
0.001 | Hepatitis C, Chronic | NA | BeFree | Detail | |
<0.001 | Heterozygous hemoglobinopathy | NA | BeFree | Detail | |
<0.001 | Inguinal lymphadenopathy | NA | BeFree | Detail | |
<0.001 | Chronic anemia | Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone m... | BeFree | 25970251 | Detail |
0.002 | Carcinogenesis | NA | BeFree | Detail | |
<0.001 | prostate carcinoma | NA | BeFree | Detail | |
0.001 | myelofibrosis | The use of biological markers including JAK2 V617 PCR test, serum EPO, PRV-1, EE... | BeFree | 16919893 | Detail |
<0.001 | Myeloproliferative disease | MPD-specific markers such as serum EPO, endogenous erythroid colony formation (E... | BeFree | 16810609 | Detail |
0.012 | polycythemia vera | As compared to their JAK2 V617F negative counterparts, the JAK2 V617F positive p... | BeFree | 18616871 | Detail |
<0.001 | Acute Megakaryocytic Leukemias | We hypothesized that the JAK2 V617F mutation might also be present in samples fr... | BeFree | 16598306 | Detail |
0.012 | polycythemia vera | Clinically suspected PV with low serum erythropoietin and absent JAK2(V617F), to... | BeFree | 20472853 | Detail |
0.003 | Leukemia, Myelocytic, Acute | We hypothesized that the JAK2 V617F mutation might also be present in samples fr... | BeFree | 16598306 | Detail |
0.012 | polycythemia vera | The role of serum erythropoietin level and JAK2 V617F allele burden in the diagn... | BeFree | 25040297 | Detail |
0.001 | myelofibrosis | Respective clustering of unfavorable and favorable cytogenetic clones in myelofi... | BeFree | 16532437 | Detail |
<0.001 | Epithelial ovarian cancer | NA | BeFree | Detail | |
0.001 | Primary myelofibrosis | The use of biological markers including JAK2 V617 PCR test, serum EPO, PRV-1, EE... | BeFree | 16919893 | Detail |
0.001 | myelofibrosis | MPD-specific markers such as serum EPO, endogenous erythroid colony formation (E... | BeFree | 16810609 | Detail |
0.012 | polycythemia vera | Half of PVSG/WHO-defined ET patients show low serum erythropoietin levels and ca... | BeFree | 25116092 | Detail |
0.001 | Primary myelofibrosis | MPD-specific markers such as serum EPO, endogenous erythroid colony formation (E... | BeFree | 16810609 | Detail |
<0.001 | Hyperplasia erythroid | Clinically suspected PV with low serum erythropoietin and absent JAK2(V617F), to... | BeFree | 20472853 | Detail |
0.002 | breast carcinoma | NA | BeFree | Detail | |
0.005 | Acute Erythroblastic Leukemia | We hypothesized that the JAK2 V617F mutation might also be present in samples fr... | BeFree | 16598306 | Detail |
0.012 | polycythemia vera | Our studies correlating the frequency of JAK2(V617F) mutant allele and clonality... | BeFree | 17198871 | Detail |
0.012 | polycythemia vera | Therefore, a contemporary approach to the diagnosis of polycythemia vera starts ... | BeFree | 20425336 | Detail |
0.002 | Thrombocythemia, Essential | The use of biological markers including JAK2 V617 PCR test, serum EPO, PRV-1, EE... | BeFree | 16919893 | Detail |
0.012 | Erythrocytosis | The objective of the present study was to evaluate the diagnostic accuracy of se... | BeFree | 25040297 | Detail |
0.019 | polycythemia | The objective of the present study was to evaluate the diagnostic accuracy of se... | BeFree | 25040297 | Detail |
0.001 | Primary myelofibrosis | Respective clustering of unfavorable and favorable cytogenetic clones in myelofi... | BeFree | 16532437 | Detail |
<0.001 | Secondary malignant neoplasm of lymph node | NA | BeFree | Detail | |
0.002 | Central neuroblastoma | NA | BeFree | Detail | |
<0.001 | diabetic macular edema | NA | BeFree | Detail | |
0.003 | Amyloidosis, Familial | NA | BeFree,LHGDN | Detail | |
<0.001 | Malignant neoplasm of kidney | NA | BeFree | Detail | |
<0.001 | Malignant Squamous Cell Neoplasm | Human tumours from oral squamous cell cancer were xenotransplanted to nude mice ... | BeFree | 25182342 | Detail |
0.080 | Hypoxia-Ischemia, Brain | NA | RGD | Detail | |
0.003 | thrombocytosis | NA | BeFree,LHGDN | Detail | |
<0.001 | BETA THALASSEMIA, HETEROZYGOUS | NA | BeFree | Detail | |
0.120 | Cardiomyopathies | NA | CTD_human | Detail | |
<0.001 | Cerebral Ischemia | NA | BeFree | Detail | |
0.005 | ovarian neoplasm | NA | LHGDN | Detail | |
<0.001 | Ischemic stroke | NA | BeFree | Detail | |
<0.001 | Sialic Acid Storage Disease, Finnish Type (disorder) | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of ovary | NA | BeFree | Detail | |
0.002 | Renal anemia | NA | BeFree | Detail | |
<0.001 | Squamous cell carcinoma of the head and neck | Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck... | BeFree | 25182342 | Detail |
<0.001 | Myxoid cyst | NA | BeFree | Detail | |
0.001 | Anemia, Diamond-Blackfan | Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone m... | BeFree | 25970251 | Detail |
0.120 | Weight decreased | NA | CTD_human | Detail | |
<0.001 | Degenerative disorder | NA | BeFree | Detail | |
<0.001 | Chronic myeloproliferative disorder | NA | BeFree | Detail | |
<0.001 | Astrocytoma, low grade | NA | BeFree | Detail | |
0.001 | Secondary polycythemia | NA | BeFree | Detail | |
<0.001 | Cerebellar hemangioblastoma | NA | BeFree | Detail | |
<0.001 | pancreatic ductal adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Treatment related acute myeloid leukaemia | NA | BeFree | Detail | |
0.001 | renal carcinoma | NA | BeFree | Detail | |
0.003 | hearing impairment | NA | LHGDN | Detail | |
<0.001 | Neonatal necrotizing enterocolitis | NA | BeFree | Detail | |
<0.001 | alpha^+^ Thalassemia | NA | BeFree | Detail | |
0.003 | Mammary Neoplasms | NA | BeFree,LHGDN | Detail | |
<0.001 | Tumor Angiogenesis | NA | BeFree | Detail | |
<0.001 | colorectal cancer | NA | BeFree | Detail | |
<0.001 | brain edema | NA | BeFree | Detail | |
0.012 | Erythrocytosis | NA | BeFree | Detail | |
<0.001 | Rash and Dermatitis Adverse Event Associated with Chemoradiation | NA | BeFree | Detail | |
0.003 | Chronic Kidney Diseases | However, treatment can result in rhEPO levels greatly exceeding the normal physi... | BeFree | 25392999 | Detail |
0.120 | Renal Insufficiency | NA | CTD_human | Detail | |
<0.001 | Polycystic Kidney - body part | NA | BeFree | Detail | |
<0.001 | tumor vasculature | NA | BeFree | Detail | |
<0.001 | Meningioma, benign, no ICD-O subtype | NA | BeFree | Detail | |
<0.001 | Amyotrophic Lateral Sclerosis, Sporadic | NA | BeFree | Detail | |
0.120 | coronary artery disease | NA | CTD_human | Detail | |
<0.001 | Parvovirus B19 (disease) | NA | BeFree | Detail | |
0.003 | Precursor Cell Lymphoblastic Leukemia Lymphoma | NA | BeFree,GAD | Detail | |
0.008 | liver carcinoma | NA | BeFree | Detail | |
0.002 | Chronic kidney disease stage 5 | NA | BeFree | Detail | |
0.120 | Acute kidney injury | NA | CTD_human | Detail | |
<0.001 | acute myeloid leukemia with myelodysplasia-related changes | NA | BeFree | Detail | |
<0.001 | Refractory anemia, without ringed sideroblasts, without excess blasts | NA | BeFree | Detail | |
<0.001 | Ischemic Cerebrovascular Accident | NA | BeFree | Detail | |
0.125 | myelodysplastic syndrome | NA | BeFree,CTD_human,GAD | Detail | |
<0.001 | Anemia in malignant neoplastic disease | NA | BeFree | Detail | |
<0.001 | Congenital Abnormality | NA | BeFree | Detail | |
0.080 | Acute-Phase Reaction | NA | RGD | Detail | |
0.001 | Primary myelofibrosis | NA | BeFree | Detail | |
<0.001 | Albinism | NA | BeFree | Detail | |
<0.001 | alpha-Thalassemia | NA | BeFree | Detail | |
<0.001 | amyloidosis | NA | BeFree | Detail | |
0.003 | amyotrophic lateral sclerosis | NA | BeFree,GAD | Detail | |
0.157 | anemia | Patients receiving combination therapy were more likely to have a haemoglobin le... | BeFree,CTD_human,LHGDN | 24747867 | Detail |
0.157 | anemia | Side effects included pruritus and anaemia leading to erythropoietin therapy. | BeFree,CTD_human,LHGDN | 25047566 | Detail |
0.157 | anemia | Anemia was the most common side effect (n = 55, 72%) requiring erythropoietin an... | BeFree,CTD_human,LHGDN | 25152985 | Detail |
0.157 | anemia | Several studies on the use of erythropoietin (Epo) to treat anaemia in patients ... | BeFree,CTD_human,LHGDN | 25182342 | Detail |
0.157 | anemia | Overall, 66% of patients experienced anaemia, leading to frequent ribavirin dose... | BeFree,CTD_human,LHGDN | 25218788 | Detail |
0.157 | anemia | Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimu... | BeFree,CTD_human,LHGDN | 25392999 | Detail |
0.157 | anemia | In addition to anemia, recent discoveries suggest new therapeutic indications fo... | BeFree,CTD_human,LHGDN | 25630969 | Detail |
0.157 | anemia | The EPO genotype in Chinese patients with type 2 diabetes is associated with ane... | BeFree,CTD_human,LHGDN | 25656761 | Detail |
0.157 | anemia | Our discovery of the role of PPAR-α agonists in stimulating self-renewal of earl... | BeFree,CTD_human,LHGDN | 25970251 | Detail |
0.157 | anemia | Accelerating Epo production in hepatocytes is one plausible therapeutic strategy... | BeFree,CTD_human,LHGDN | 26012551 | Detail |
0.002 | Anemia of chronic disease | Anemia of chronic disease is a multifactorial disorder, resulting mainly from in... | BeFree | 24895335 | Detail |
<0.001 | aplastic anemia | NA | BeFree | Detail | |
<0.001 | Cooley's anemia | NA | BeFree | Detail | |
0.121 | Anemia, Hemolytic | NA | BeFree,CTD_human | Detail | |
<0.001 | Anemia, Hemolytic, Congenital | NA | BeFree | Detail | |
<0.001 | Refractory anemias | NA | BeFree | Detail | |
<0.001 | Refractory anaemia with excess blasts | NA | BeFree | Detail | |
<0.001 | Anemia, Sickle Cell | Erythropoietin-mediated expression of placenta growth factor is regulated via ac... | BeFree | 25876995 | Detail |
<0.001 | sideroblastic anemia | NA | BeFree | Detail | |
0.016 | Anoxia | NA | LHGDN | Detail | |
<0.001 | Anxiety Disorders | NA | BeFree | Detail | |
<0.001 | Ataxia | NA | BeFree | Detail | |
<0.001 | Autoimmune Diseases | NA | BeFree | Detail | |
0.121 | beta thalassemia | NA | BeFree,CTD_human | Detail | |
<0.001 | Blast Phase | NA | BeFree | Detail | |
<0.001 | Brain Diseases | NA | BeFree | Detail | |
<0.001 | Brain Neoplasms | NA | BeFree | Detail | |
0.002 | Malignant neoplasm of breast | NA | BeFree | Detail | |
0.120 | calcinosis | NA | CTD_human | Detail | |
0.001 | Non-small cell lung carcinoma | NA | BeFree | Detail | |
0.006 | renal cell carcinoma | NA | BeFree,LHGDN | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
Human tumours from oral squamous cell cancer were xenotransplanted to nude mice treated with Epo. | DisGeNET | Detail |
However, until now only a handful number of genetic variants were reported to be associated with eit... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
However, until now only a handful number of genetic variants were reported to be associated with eit... | DisGeNET | Detail |
However, until now only a handful number of genetic variants were reported to be associated with eit... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The EPO genotype in Chinese patients with type 2 diabetes is associated with anemia and may help to ... | DisGeNET | Detail |
Genetic variants in angiotensin-converting enzyme (ACE), tumor necrosis factor-alpha (TNF-α) and ery... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The loss of all PHD isoforms results in both polycythemia, which is caused by Epo overproduction, an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Therefore, pEpo-NI2-SV-HSVtk/PEI-Dexa complex may be useful for glioblastoma-specific gene therapy. | DisGeNET | Detail |
It has been recently reported that erythropoietin (EPO) and its receptor (EPOR) are involved in glio... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
However, treatment can result in rhEPO levels greatly exceeding the normal physiological range for e... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Recombinant human erythropoietin augments angiogenic responses in a neonatal rat model of cerebral u... | DisGeNET | Detail |
Accelerating Epo production in hepatocytes is one plausible therapeutic strategy for treating anemia... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Our study suggests one possible mechanism by which some uterine leiomyomas reach a large size, and t... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplementation, respectively... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplementation, respectively... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone marrow failure diseas... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Due to the unique association of patients' polycythemia with borderline or mildly elevated erythropo... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
However, until now only a handful number of genetic variants were reported to be associated with eit... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Aberrant expression of erythropoietin in uterine leiomyoma: implications in tumor growth. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Some patients with primary hereditary erythrocytosis exhibit a mutation in the erythropoietin recept... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Interestingly, the highest level of EPO/% retic ratio as indicated for EPO non-responder was detecte... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The aim of this study is to explore a cause-oriented therapy for patients with uterine cervical canc... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone marrow failure diseas... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The use of biological markers including JAK2 V617 PCR test, serum EPO, PRV-1, EEC, leukocyte alkalin... | DisGeNET | Detail |
MPD-specific markers such as serum EPO, endogenous erythroid colony formation (EEC), and JAK2 V617F ... | DisGeNET | Detail |
As compared to their JAK2 V617F negative counterparts, the JAK2 V617F positive patients had PV-like ... | DisGeNET | Detail |
We hypothesized that the JAK2 V617F mutation might also be present in samples from patients with acu... | DisGeNET | Detail |
Clinically suspected PV with low serum erythropoietin and absent JAK2(V617F), together with the bone... | DisGeNET | Detail |
We hypothesized that the JAK2 V617F mutation might also be present in samples from patients with acu... | DisGeNET | Detail |
The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemi... | DisGeNET | Detail |
Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The use of biological markers including JAK2 V617 PCR test, serum EPO, PRV-1, EEC, leukocyte alkalin... | DisGeNET | Detail |
MPD-specific markers such as serum EPO, endogenous erythroid colony formation (EEC), and JAK2 V617F ... | DisGeNET | Detail |
Half of PVSG/WHO-defined ET patients show low serum erythropoietin levels and carry the JAK2(V617F) ... | DisGeNET | Detail |
MPD-specific markers such as serum EPO, endogenous erythroid colony formation (EEC), and JAK2 V617F ... | DisGeNET | Detail |
Clinically suspected PV with low serum erythropoietin and absent JAK2(V617F), together with the bone... | DisGeNET | Detail |
NA | DisGeNET | Detail |
We hypothesized that the JAK2 V617F mutation might also be present in samples from patients with acu... | DisGeNET | Detail |
Our studies correlating the frequency of JAK2(V617F) mutant allele and clonality, as well as the pre... | DisGeNET | Detail |
Therefore, a contemporary approach to the diagnosis of polycythemia vera starts with peripheral bloo... | DisGeNET | Detail |
The use of biological markers including JAK2 V617 PCR test, serum EPO, PRV-1, EEC, leukocyte alkalin... | DisGeNET | Detail |
The objective of the present study was to evaluate the diagnostic accuracy of serum EPO and JAK2 V61... | DisGeNET | Detail |
The objective of the present study was to evaluate the diagnostic accuracy of serum EPO and JAK2 V61... | DisGeNET | Detail |
Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Human tumours from oral squamous cell cancer were xenotransplanted to nude mice treated with Epo. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carci... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone marrow failure diseas... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
However, treatment can result in rhEPO levels greatly exceeding the normal physiological range for e... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Patients receiving combination therapy were more likely to have a haemoglobin level of <8.5 g/dL (70... | DisGeNET | Detail |
Side effects included pruritus and anaemia leading to erythropoietin therapy. | DisGeNET | Detail |
Anemia was the most common side effect (n = 55, 72%) requiring erythropoietin and RBV dose reduction... | DisGeNET | Detail |
Several studies on the use of erythropoietin (Epo) to treat anaemia in patients undergoing cancer tr... | DisGeNET | Detail |
Overall, 66% of patients experienced anaemia, leading to frequent ribavirin dose reductions (42%) an... | DisGeNET | Detail |
Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin... | DisGeNET | Detail |
In addition to anemia, recent discoveries suggest new therapeutic indications for EPO, unrelated to ... | DisGeNET | Detail |
The EPO genotype in Chinese patients with type 2 diabetes is associated with anemia and may help to ... | DisGeNET | Detail |
Our discovery of the role of PPAR-α agonists in stimulating self-renewal of early erythroid progenit... | DisGeNET | Detail |
Accelerating Epo production in hepatocytes is one plausible therapeutic strategy for treating anemia... | DisGeNET | Detail |
Anemia of chronic disease is a multifactorial disorder, resulting mainly from inflammation-driven re... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs386626619 dbSNP
- Genome
- hg19
- Position
- chr7:100,318,091-100,321,323
- Variant Type
- snv
Genome browser